Asia-Pacific’s consumer industry saw a drop of 20.17% in deal activity during August 2022, when compared with the last 12-month average, led by Cooke’s $1.01bn acquisition of Tassal Group, according to GlobalData’s deals database.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 95 consumer industry deals worth $1.5bn were announced for the region in August 2022, against the 12-month average of 119 deals.
Of all the deal types, venture financing saw most activity in August 2022 with 57 transactions, representing a 60% share for the region.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn second place was M&A with 32 deals, followed by private equity deals with six transactions, respectively capturing a 33.7% and 6.3% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in Asia-Pacific’s consumer industry with $1.1bn, while venture financing and private equity deals totalled $354.86m and $11.35m, respectively.
Asia-Pacific consumer industry deals in August 2022: Top deals
The top five consumer deals accounted for 88.9% of the overall value during August 2022.
The combined value of the top five consumer deals stood at $1.31bn, against the overall value of $1.5bn recorded for the month.
The top five consumer industry deals of August 2022 tracked by GlobalData were:
1) Cooke’s $1.01bn acquisition deal with Tassal Group
2) The $148.28m venture financing of Xiangdao Chuxing by Gaoxing Management Consulting, Momenta Group and SAIC Motor
3) GGV Capital and Temasek Holdings (Private)’s $65.5m venture financing deal with Oatside
4) The $50m venture financing of Hector Beverages by GIC
5) Tus Pharmaceutical Group’s $32.54m acquisition deal with Guangdong Xiantong Pharmaceutical
